Panitumumab Plus 5-FU/Leucovorin Maintenance Improves PFS in RAS Wild-Type Metastatic CRC
The addition of panitumumab to 5-fluorouracil and leucovorin significantly improved progression-free survival as a maintenance treatment over 5-FU/leucovorin alone in patients with RAS wild-type metastatic colorectal cancer.
Dr. Zalcberg on the Efficacy of Intra-Patient Dose Escalation With Ripretinib in Advanced GIST
June 7th 2021John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.
Tisagenlecleucel Induces High Rates of Durable Response in Relapsed/Refractory Follicular Lymphoma
June 7th 2021Tisagenlecleucel led to a high response rate that proved durable, along with a favorable safety profile, in patients with relapsed/refractory follicular lymphoma following treatment with at least 2 prior regimens, according to interim findings from the phase 2 ELARA trial.
Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC
June 7th 2021The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.
HRQOL Analysis Further Supports Pembrolizumab/Lenvatinib for Frontline RCC
June 7th 2021Frontline treatment with the combination of lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma led to similar health-related quality of life outcomes and disease-related symptom scores vs sunitinib.
Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer
June 7th 2021Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.